Novavax (NASDAQ:NVAX) shares lost ~12% in the premarket on Tuesday after the Gaithersburg, MD-based biotech, with its Q3 2024 ...
BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
On 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health ...
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
Novavax (NVAX) delivered earnings and revenue surprises of 12.64% and 47.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts are estimating that Novavax will report an earnings per share (EPS) of $-0.87. Anticipation surrounds Novavax's ...
J.P. Morgan analyst Eric Joseph maintained a Sell rating on Novavax (NVAX – Research Report) yesterday and set a price target of $9.00. Eric Joseph has given his Sell rating due to a combination of ...